Rostro Group Enters UAE with New SCA Licence Amid the Country’s 20% Fintech Growth Surge
Ingelheim, Germany, Mon, 16/09/2024 – 12:00 Boehringer Ingelheim announced today that the FIBRONEER™-IPF trial met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] (FVC) at week 52 versus placebo. FVC is Read More



